SAB Biotherapeutics, Inc.
SABS•NASDAQ•Healthcare•Biotechnology

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOSamuel Reich
Founded2014
Employees63
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.sabbiotherapeutics.com
Phone605 679 6980
Address
777 W 41st St. Miami Beach, Florida 33140 United States

Corporate Identifiers

CIK0001833214
CUSIP78397T103
ISINUS78397T2024
EIN85-3899721
SIC2836

Leadership Team & Key Executives

Samuel J. Reich
Chairman and Chief Executive Officer
Dr. Eddie Joe Sullivan Ph.D.
Co-Founder, President and Director
Lucy To
Executive Vice President and Chief Financial Officer
Dr. Christoph Bausch M.B.A., Ph.D.
Executive Vice President and Chief Operating Officer
Dr. Alexandra Kropotova M.B.A., M.D.
Executive Vice President and Chief Medical Officer
Catherine DeRose
Vice President of Human Resources
Hua Wu Ph.D.
Senior Vice President of Product Development
Dr. Carlos N. Carillo M.Sc., Ph.D.
Senior Vice President of Regulatory Affairs
Angie Parizek
Senior Vice President of Clinical Operations